

Errata

Cite as: *Can Urol Assoc J* 2020;14(12):E643. <http://dx.doi.org/10.5489/cuaj.7069>

Erratum 1 – Table revisions for MY-T study

In the paper entitled, “MY-T study: Symptom-based titration decisions when using testosterone nasal gel, Natesto[®],” (Citation: *Can Urol Assoc J* 2019;13(10):301-6. <http://dx.doi.org/10.5489/cuaj.5662>), there were errors in Table 3, “Mean hematocrit values by visit and dose (safe population).”

CUAJ regrets the oversight and apologizes for any inconvenience. Visit <https://cuaj.ca/index.php/journal/article/view/5662/4202> for a corrected version of the data, which is also included below.

Erratum 2 – Author revision in NSAUA 2019 abstracts

In the NSAUA 2019 abstracts (Citation: *Can Urol Assoc J* 2019;13(9Suppl6):S173-208. <http://dx.doi.org/10.5489/cuaj.6197>), author A. Christophe was missing from the author list of abstract #MP5-20, “Improving situation awareness for the console surgeon utilizing a live bedside video feed: A feasibility study.”

The authors should have been listed as follows:

M. Durrani¹, N. Aldhaam¹, A. Elsayed¹, A. Christophe¹, Y. Fu², Q. Zhang², L. Cavuoto², A. Hussein¹, K. Guru¹

¹Roswell Park Comprehensive Cancer Center; ²University at Buffalo

Table 3. Mean hematocrit values by visit and dose (safety population)

Parameter	All patients	BID	TID
Baseline (visit 1) (mean) (SD, n)	45.36 (5.35, 115)	45.43 (5.58, 85)	45.16 (4.72, 30)
Day 90 (visit 4 BID dose) (mean) (SD, n)	44.43 (3.65, 72)	44.28 (3.43, 44)*	44.67 (4.02, 28)
Day 120 (visit 5 TID dose) (mean) (SD, n)	43.76 (2.44, 22)*	NA	43.76 (2.44, 22)*

*Statistically significant ($p < 0.05$) from visit 1 to visit 4 and from visit 1 to visit 5. BID: twice daily; TID: three times daily; SD: standard deviation.